Uveal Melanoma – Pipeline Review, 2019

Uveal melanoma, also referred to as intraocular melanoma is an ocular disease in which malignant cells develop in the inner tissues of the eye. According to the National Cancer Institute, uveal melanoma is a rare form of cancer but still is one of the most prevalent eye cancers in adults. Malignant tissues develop in the cells that make up melanin in the iris choroid and ciliary body. The symptoms include dark spots on the iris and blurred vision. The estimates provided by the National Cancer Institute states that there are an estimated 5.1 cases of uveal melanoma per million per year, globally.

There is no definitive Food and Drug Administration (FDA) approved standard of care for the treatment of uveal melanoma in the current scenario. Depending upon the stage of the melanoma, the treatment options include radiation therapy, plaque brachytherapy, enucleation (surgical removal of the eye) and use of chemotherapeutic agents like dacarbazine.

Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for uveal melanoma. For instance; Crizotinib, which is being studied by Pfizer Inc., is in Phase-2 clinical trial for testing the efficacy of Crizotinib in patients with uveal melanoma.

In 2018, an estimated 64.0% of the pipeline candidates for uveal melanoma were in Phase 2 stage. Most of the studies are being conducted by research institutes and pharmaceutical companies.

Report Description

The report on ‘Uveal Melanoma – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Uveal Melanoma. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Uveal Melanoma.

The report on ‘Uveal Melanoma – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Uveal Melanoma
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Uveal Melanoma
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary